CoChat
Sign Up
Cited by 377Chronic Kidney Disease and DiabetesRenal Diseases and GlomerulopathiesAdvanced Glycation End Products research

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

Open access
Cooper, M. E.·2001·Diabetologia
DOI 10.1007/s001250100000
Open this paper in CoChat — free accountOpen PDF

Abstract

Diabetic nephropathy seems to occur as a result of an interaction of metabolic and haemodynamic factors. Glucose dependent pathways are activated within the diabetic kidney. These include increased oxidative stress, renal polyol formation and accumulation of advanced glycated end-products. Haemodynamic factors are also implicated in the pathogenesis of diabetic nephropathy and include increased systemic and intraglomerular pressure and activation of various vasoactive hormone pathways including the renin-angiotensin system and endothelin. These haemodynamic pathways, independently and with metabolic pathways, activate intracellular second messengers such as protein kinase C and MAP kinase, nuclear transcription factors such as NF-kappaB and various growth factors such as the prosclerotic cytokine, TGF-beta and the angiogenic, permeability enhancing growth factor, VEGF. These pathways ultimately lead to increased renal albumin permeability and extracellular matrix accumulation which results in increasing proteinuria, glomerulosclerosis and tubulointerstitial fibrosis. Therapeutic strategies involved in the management and prevention of diabetic nephropathy include currently available treatments such as intensified glycaemic control and antihypertensive agents, particularly those which interrupt the renin-angiotensin system. More novel strategies to influence vasoactive hormone action or to inhibit various metabolic pathways such as inhibitors of advanced glycation, specific protein kinase C isoforms and aldose reductase are at present under experimental and clinical investigation. It is predicted that multiple therapies will be required to reduce the progression of diabetic nephropathy.

Overview

Integrity signals

Registry

Crossref · 10.1007/s001250100000

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 14 references

Cited by

Sorted by citations

Items 301–377 of 377

Related

See all

Metadata

Authors
Cooper, M. E.
Affiliations
The University of Melbourne (AU)
Corresponding author
Cooper, M. E.
ORCID
Cooper, M. E.
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2001-11-01
Volume
44
Issue
11
Pages
1957-1972
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
DOI
10.1007/s001250100000
OpenAlex
W1991427290
Cited by
375
References
14
Citations by year
2026: 5 · 2025: 4 · 2024: 10 · 2023: 14 · 2022: 5 · 2021: 19 · 2020: 16 · 2019: 9 · 2018: 8 · 2017: 15 · 2016: 13 · 2015: 10 · 2014: 23 · 2013: 20 · 2012: 14
FWCI
4.27
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
Funders
Kidney Health Australia
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
diabetic nephropathy, metabolic factors, oxidative stress, advanced glycation end products, intraglomerular pressure, renin-angiotensin system, endothelin, protein kinase C, mitogen-activated protein kinase, NF-κB, TGF-beta, vascular endothelial growth factor, albumin permeability, extracellular matrix accumulation, glomerulosclerosis, tubulointerstitial fibrosis, proteinuria, aldose reductase inhibitors, renin-angiotensin system inhibitors, antihypertensive therapy, glycemic control, pathogenesis
MeSH terms
Animals, Diabetic Nephropathies, Diabetic Retinopathy, Disease Models, Animal, Hemodynamics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review